[{"id":"2360563a-7ee0-45bc-b686-a50af2502a4a","acronym":"DAPA-ARMOR","url":"https://clinicaltrials.gov/study/NCT07018622","created_at":"2025-06-14T13:56:13.578Z","updated_at":"2025-06-14T13:56:13.578Z","phase":"Phase 2","brief_title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","source_id_and_acronym":"NCT07018622 - DAPA-ARMOR","lead_sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","biomarkers":" B2M","pipe":"","alterations":" ","tags":["B2M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • carboplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 05/07/2025","start_date":" 05/07/2025","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2025-06-12"},{"id":"aecf3ac5-9504-4f3a-9a5f-7cc5aaedb65d","acronym":"NCI-2019-03212","url":"https://clinicaltrials.gov/study/NCT03965689","created_at":"2021-01-18T19:30:37.082Z","updated_at":"2024-07-02T16:35:02.796Z","phase":"Phase 2","brief_title":"Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy","source_id_and_acronym":"NCT03965689 - NCI-2019-03212","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression","tags":["BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 03/20/2025","study_completion_date":" 03/20/2025","last_update_posted":"2024-05-17"},{"id":"a8c65941-392d-4c78-b64d-bcf83077b940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02320292","created_at":"2021-01-18T11:00:10.127Z","updated_at":"2024-07-02T16:35:29.118Z","phase":"Phase 3","brief_title":"Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma","source_id_and_acronym":"NCT02320292","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2 • B2M","pipe":" | ","alterations":" BCL2 mutation","tags":["BCL2 • B2M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • Zevalin (ibritumomab tiuxetan) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 02/11/2015","start_date":" 02/11/2015","primary_txt":" Primary completion: 02/28/2021","primary_completion_date":" 02/28/2021","study_txt":" Completion: 11/09/2023","study_completion_date":" 11/09/2023","last_update_posted":"2023-11-15"},{"id":"8b9deff6-aed3-4ebb-85e2-b058cc2a2aca","acronym":"MYLACRE","url":"https://clinicaltrials.gov/study/NCT03955900","created_at":"2021-01-18T19:28:09.798Z","updated_at":"2024-07-02T16:35:53.832Z","phase":"","brief_title":"A Registry Study of Participants With Multiple Myeloma in Latin America","source_id_and_acronym":"NCT03955900 - MYLACRE","lead_sponsor":"Janssen-Cilag Ltd.","biomarkers":" B2M","pipe":"","alterations":" ","tags":["B2M"],"overall_status":"Completed","enrollment":" Enrollment 2059","initiation":"Initiation: 05/29/2019","start_date":" 05/29/2019","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2023-03-07"},{"id":"f22b88d8-7426-4a53-a629-86b06e924f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03091127","created_at":"2021-01-18T15:13:44.772Z","updated_at":"2024-07-02T16:35:59.306Z","phase":"","brief_title":"Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe","source_id_and_acronym":"NCT03091127","lead_sponsor":"Amgen","biomarkers":" B2M","pipe":"","alterations":" ","tags":["B2M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib"],"overall_status":"Completed","enrollment":" Enrollment 705","initiation":"Initiation: 03/14/2017","start_date":" 03/14/2017","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 03/17/2020","study_completion_date":" 03/17/2020","last_update_posted":"2022-12-12"},{"id":"a5f01798-3d5c-4304-a734-2a02d3250780","acronym":"Onco-PDL1s/B2M","url":"https://clinicaltrials.gov/study/NCT05426317","created_at":"2022-06-22T22:53:59.016Z","updated_at":"2024-07-02T16:36:08.473Z","phase":"","brief_title":"Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression","source_id_and_acronym":"NCT05426317 - Onco-PDL1s/B2M","lead_sponsor":"University Hospital, Clermont-Ferrand","biomarkers":" PD-L1 • B2M","pipe":"","alterations":" ","tags":["PD-L1 • B2M"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 02/10/2022","start_date":" 02/10/2022","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2022-06-22"},{"id":"b8578e8d-7833-452c-bdde-46cc07292ef8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05046366","created_at":"2021-09-16T14:52:58.365Z","updated_at":"2024-07-02T16:36:20.666Z","phase":"","brief_title":"Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.","source_id_and_acronym":"NCT05046366","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" MUC1 • CEACAM5 • B2M • KRT19 • CRP","pipe":"","alterations":" ","tags":["MUC1 • CEACAM5 • B2M • KRT19 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-11-16"},{"id":"a72da2dc-7450-4c51-9294-72a72e94626d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03273751","created_at":"2021-01-18T16:10:08.222Z","updated_at":"2024-07-02T16:36:22.680Z","phase":"","brief_title":"The Effect of Remote Ischemic Preconditioning on Kidney Function in Patients Undergoing Partial Nephrectomy","source_id_and_acronym":"NCT03273751","lead_sponsor":"Seoul National University Hospital","biomarkers":" B2M • OGA","pipe":"","alterations":" ","tags":["B2M • OGA"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 08/28/2018","primary_completion_date":" 08/28/2018","study_txt":" Completion: 08/28/2018","study_completion_date":" 08/28/2018","last_update_posted":"2021-10-21"},{"id":"95510857-a011-4a07-85a6-99325885af25","acronym":"RECORDER","url":"https://clinicaltrials.gov/study/NCT02950389","created_at":"2021-01-18T14:29:28.588Z","updated_at":"2024-07-02T16:36:33.118Z","phase":"","brief_title":"REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs","source_id_and_acronym":"NCT02950389 - RECORDER","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" B2M","pipe":"","alterations":" ","tags":["B2M"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2021-03-18"},{"id":"077d9162-d559-485c-9149-55c8476adb7a","acronym":"THERANOVA","url":"https://clinicaltrials.gov/study/NCT03211676","created_at":"2021-01-18T15:50:25.999Z","updated_at":"2024-07-02T16:36:46.078Z","phase":"","brief_title":"Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer","source_id_and_acronym":"NCT03211676 - THERANOVA","lead_sponsor":"Poitiers University Hospital","biomarkers":" IL6 • TNFA • B2M • FGF23 • IL1B • LEP • MB","pipe":"","alterations":" ","tags":["IL6 • TNFA • B2M • FGF23 • IL1B • LEP • MB"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 06/07/2017","start_date":" 06/07/2017","primary_txt":" Primary completion: 03/14/2018","primary_completion_date":" 03/14/2018","study_txt":" Completion: 06/14/2018","study_completion_date":" 06/14/2018","last_update_posted":"2020-04-13"},{"id":"7b021f87-6706-4995-b612-bcc8bea2b002","acronym":"","url":"https://clinicaltrials.gov/study/NCT01611090","created_at":"2021-01-18T06:53:55.340Z","updated_at":"2024-07-02T16:36:49.300Z","phase":"Phase 3","brief_title":"A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT01611090","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" B2M","pipe":"","alterations":" ","tags":["B2M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 578","initiation":"Initiation: 09/19/2012","start_date":" 09/19/2012","primary_txt":" Primary completion: 01/23/2019","primary_completion_date":" 01/23/2019","study_txt":" Completion: 01/23/2019","study_completion_date":" 01/23/2019","last_update_posted":"2020-03-03"},{"id":"2c2e629d-eb16-49d0-abf9-c2188f97a591","acronym":"BRCAP-GELTAMO12","url":"https://clinicaltrials.gov/study/NCT01848132","created_at":"2021-01-18T08:14:49.753Z","updated_at":"2024-07-02T16:37:06.740Z","phase":"Phase 2","brief_title":"Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.","source_id_and_acronym":"NCT01848132 - BRCAP-GELTAMO12","lead_sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","biomarkers":" CD20 • B2M","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • B2M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 121","initiation":"Initiation: 10/03/2013","start_date":" 10/03/2013","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2018-09-19"},{"id":"741f1d23-8352-458a-8b74-c72114763cb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01520922","created_at":"2021-01-18T06:23:52.354Z","updated_at":"2025-02-25T13:17:28.181Z","phase":"Phase 2","brief_title":"Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)","source_id_and_acronym":"NCT01520922","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD20 • IGH • CD79B • B2M • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • IGH • CD79B • B2M • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2017-01-19"},{"id":"7ef03ec1-b18c-4029-b154-49641bcbc76a","acronym":"MUTEX","url":"https://clinicaltrials.gov/study/NCT01450319","created_at":"2021-01-18T06:01:10.414Z","updated_at":"2025-02-25T14:49:30.598Z","phase":"Phase 2","brief_title":"Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype","source_id_and_acronym":"NCT01450319 - MUTEX","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" EGFR • KRAS • B2M • FCGR2A • FCGR2B • KIR2DS4","pipe":" | ","alterations":" KRAS mutation • EGFR expression • RAS mutation","tags":["EGFR • KRAS • B2M • FCGR2A • FCGR2B • KIR2DS4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2016-11-28"}]